



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



UPGL00004

Cat. No.:	HY-119377
CAS No.:	1890169-95-5
Molecular Formula:	C ₂₅ H ₂₆ N ₈ O ₂ S ₂
Molecular Weight:	534.66
Target:	Glutaminase
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (233.79 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.8703 mL	9.3517 mL	18.7035 mL
	5 mM		0.3741 mL	1.8703 mL	3.7407 mL
	10 mM		0.1870 mL	0.9352 mL	1.8703 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC ₅₀ =29 nM; K _d =27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines ^[1] .
IC ₅₀ & Target	IC ₅₀ : 29 nM (Glutaminase C) ^[1] K _d : 27 nM (Glutaminase C) ^[1]
In Vitro	UPGL00004 inhibits MDA-MB-231, HS578T and TSE cells with IC ₅₀ s of 70, 129, and 262 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The combination of UPGL00004 (1 mg/kg body weight) and Bevacizumab (2.5 mg/kg body weight) via intraperitoneal injection completely prevent any detectable increase in tumor size in a triple-negative breast cancer patient-derived tumor graft model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA